Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran

Abstract

We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates. In our study antibiotic susceptibility testing, double disk synergy test, modified Hodge test were applied. Detection of ESBL, AmpC, and carbapenemase genes was performed by PCR. Multilocus sequence typing (MLST) analysis was done on OXA-48 producing K. pneumoniae strains. Our results showed that among E. coli and K. pneumoniae isolates, 41.1% and 40% of strains produced ESBL, respectively. Additionally, the prevalence of AmpC producing K. pneumoniae and E. coli was 4% and 45.5%, respectively. Altogether 64.2% of K. pneumoniae strains and one E. coli isolate produced carbapenemase. Among OXA-48 producing K. pneumoniae strains ST3500 and ST2528 were detected by MLST. Based on the phenotypic results of this study, vaborbactam was an effective inhibitor on the third-generation cephalosporin-resistant isolates (P < 0.0001). Meropenem-vaborbactam combination had the highest efficacy on KPC producing strains, and it had limited activity on isolates producing OXA-48 type beta-lactamases, whereas no effect was observed on NDM-1 producing isolates. Our study provided valuable information regarding the vaborbactam inhibitory effect on β-lactamase-producing strains.

A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli

“…The combination of meropenem and vaborbactam was most effective against KPC-producing bacteria, whereas it was ineffective against isolates that produced β -lactamases of the OXA-48 type. Our research was really useful in understanding how vaborbactam inhibits β -lactamase-producing bacteria ( Amereh et al., 2022 ).…”

Molecular Characterization of Carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Erbil, Iraq

“…E. coli & K. pneumoniae respectively are the leading cause for urinary tract infection and bloodstream infection (6). The blaOXA-48 gene was selected due to its endemicity in the neighboring country Turkey, (7) , whereas blaNDM-1 which is endemic in India (8), while many cases have been reported from Saudi Arabia, Iran, and Turkey (9)(10)(11). This affected Kurdish people who are traveling to these endemic countries for medical treatments, tourism, pilgrimage, and the acquisition of this resistant genes after admission or performing surgical procedures in their hospitals.…”